Literature DB >> 6488172

Differential effects of 12-O-tetradecanoylphorbol-13-acetate on cultured normal and neoplastic human bronchial epithelial cells.

J C Willey, C E Moser, J F Lechner, C C Harris.   

Abstract

The effects of the tumor promoter 12-O-tetradecanoylphorbol-13-acetate (TPA) on 10 human lung carcinoma cell lines were compared to those seen on normal human bronchial epithelial (NHBE) cells. TPA (0.1 to 100 nM) did not enhance the clonal growth rate for any of the cell lines. As little as 3 nM TPA induced the NHBE cells to undergo terminal squamous differentiation and thus completely inhibited their proliferation; in contrast, none of the carcinoma cell lines was significantly inhibited at this concentration, and they all continued to proliferate in as much as 100 nM TPA. To determine if this lack of TPA inhibition of clonal growth reflected resistance to TPA induction of terminal squamous differentiation, we measured the ability of TPA to induce cross-linked envelope formation and to increase plasminogen activator activity in four carcinoma cell lines. Cross-linked envelopes were not induced in two lines, and only a small number were induced in the other two lines relative to NHBE cells; plasminogen activator activity was induced in NHBE cells but not in any of the cell lines.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6488172

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  14 in total

1.  All-trans retinoic acid converts E2F into a transcriptional suppressor and inhibits the growth of normal human bronchial epithelial cells through a retinoic acid receptor- dependent signaling pathway.

Authors:  H Y Lee; D F Dohi; Y H Kim; G L Walsh; U Consoli; M Andreeff; M I Dawson; W K Hong; J M Kurie
Journal:  J Clin Invest       Date:  1998-03-01       Impact factor: 14.808

Review 2.  Use of cultured human tissues and cells in carcinogenesis research.

Authors:  E W Gabrielson; C C Harris
Journal:  J Cancer Res Clin Oncol       Date:  1985       Impact factor: 4.553

3.  Transforming growth factor beta1 induces differentiation in human papillomavirus-positive keratinocytes.

Authors:  M A Ozbun; C Meyers
Journal:  J Virol       Date:  1996-08       Impact factor: 5.103

4.  Transformed human bronchial epithelial cells (BEAS-2B) alter the growth and morphology of normal human bronchial epithelial cells in vitro.

Authors:  C D Albright; R T Jones; E A Hudson; J A Fontana; B F Trump; J H Resau
Journal:  Cell Biol Toxicol       Date:  1990-10       Impact factor: 6.691

5.  Growth regulation of serum-free cultures of epithelial cells from normal human buccal mucosa.

Authors:  K Sundqvist; Y Liu; K Arvidson; K Ormstad; L Nilsson; R Toftgård; R C Grafström
Journal:  In Vitro Cell Dev Biol       Date:  1991-07

6.  An Eastern Cooperative Oncology Group phase I trial of all-trans-retinoic acid and interferon-alpha: E2Y92.

Authors:  J H Schiller; D Neuberg; D Burns; P Ritch; M Larson; M Levitt; J Dutcher
Journal:  Invest New Drugs       Date:  1997       Impact factor: 3.850

7.  Characterization of primary human keratinocytes transformed by human papillomavirus type 18.

Authors:  P Kaur; J K McDougall
Journal:  J Virol       Date:  1988-06       Impact factor: 5.103

8.  Induction of transformation of human respiratory epithelium in vitro. Preliminary investigation.

Authors:  P Koldovsky; H Bier; U Ganzer
Journal:  Eur Arch Otorhinolaryngol       Date:  1992       Impact factor: 2.503

9.  Type beta transforming growth factor is the primary differentiation-inducing serum factor for normal human bronchial epithelial cells.

Authors:  T Masui; L M Wakefield; J F Lechner; M A LaVeck; M B Sporn; C C Harris
Journal:  Proc Natl Acad Sci U S A       Date:  1986-04       Impact factor: 11.205

10.  Stable low-level expression of p21WAF1/CIP1 in A549 human bronchogenic carcinoma cell line-derived clones down-regulates E2F1 mRNA and restores cell proliferation control.

Authors:  Timothy G Graves; Michael W Harr; Erin L Crawford; James C Willey
Journal:  Mol Cancer       Date:  2006-01-10       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.